Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company based in Tokyo, Japan, and ranks as the second-largest pharmaceutical company in the country by revenue. Established in 2005 through the merger of Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited, it has a rich history of over 100 years. The company operates in more than 20 countries, with significant subsidiaries in the United States and Europe. Daiichi Sankyo focuses on the research, development, manufacturing, and marketing of innovative pharmaceutical products, particularly in oncology and cardiovascular therapies. Its notable products include Prasugrel, an antiplatelet agent, Inavir, an anti-influenza virus agent, and Rezaltas, a cardiovascular medication. The company is dedicated to addressing unmet medical needs and improving patient outcomes through its diverse portfolio and global reach, serving healthcare providers, hospitals, and pharmacies worldwide.